Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
571
datasets available to search
ShareScore release 0.9.0
Dataset results
571 results for “CLL”
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
ClinicalTrials.gov study NCT00648739. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
ClinicalTrials.gov study NCT03824483. IPD Sharing: YES. Countries: 1. Publications: 2.
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT00759798. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small L
ClinicalTrials.gov study NCT04666038. IPD Sharing: Not stated. Countries: 24. Publications: 1.
AID overexpression leads to aggressive murine CLL and non-Ig mutations that mirror human neoplasms
<p></p><p>Most cancers become more dangerous by the outgrowth of malignant subclones with additional DNA mutations that favor proliferation or survival. Using chronic lymphocytic leukemia (CLL), a disease exemplary of this process, and a model for neoplasms in general, we created transgenic mice overexpressing the enzyme, activation-induced deaminase (AID), whose normal function is to induce DNA mutations in B lymphocytes. AID allows normal B lymphocytes to develop more effective immunoglobulin (Ig)-mediated immunity, but also is able to mutate non-Ig genes, predisposing to cancer. In chronic lymphocytic leukemia (CLL), AID expression correlates with poor prognosis suggesting a role for this enzyme in disease progression. Nevertheless, direct experimental evidence identifying the specific genes that are mutated by AID and indicating that those genes are associated with disease progression is not available. To address this point, we overexpressed Aicda in a murine model of CLL (Em-TCL1). Analyses of TCL1/AID mice demonstrate a role for AID in disease kinetics, CLL-cell proliferation, and the development of cancer-related target mutations with canonical AID signatures in non-Igs genes. Notably, our mouse models can accumulate mutations in the same genes that are mutated in human cancers. Moreover, some of these mutations occur at homologous positions, leading to identical or chemically-similar amino acid substitutions as in human CLL and lymphoma. Together, these findings support a direct link between aberrant AID activity and CLL driver mutations that are then selected for their oncogenic effects, whereby AID promotes aggressiveness in CLL and other B-cell neoplasms.</p><p></p>
FIGURE. Results of discriminant function an alysis (DFA) for C. brizoides (br), C. curvata (cu) and C. praecox (pr). Characters abbreviated as in Table 2. A. Reproductive characters. Loadings for the first axis (only absolute values>0.50 are given): LB = 0.63, LN = -0.93, WN = 0.94, LN/WN = 1.13, FGL = -0.62. Loadings for the second axis: WW = -0.76, LB = 1.51, LN = 2.21, WN = -1.79, LN/WN = -1.48, FGL = 0.55, FGW = -0.51. B. Vegetative characters. Loadings for the first axis (only absolute values>0.50 are given): CLL = -0.58. Loadings for the second axis: CW = -0.72, IL = -0.78. in Carex section Ammoglochin (Cyperaceae) in Poland
FIGURE. Results of discriminant function an alysis (DFA) for C. brizoides (br), C. curvata (cu) and C. praecox (pr). Characters abbreviated as in Table 2. A. Reproductive characters. Loadings for the first axis (only absolute values>0.50 are given): LB = 0.63, LN = -0.93, WN = 0.94, LN/WN = 1.13, FGL = -0.62. Loadings for the second axis: WW = -0.76, LB = 1.51, LN = 2.21, WN = -1.79, LN/WN = -1.48, FGL = 0.55, FGW = -0.51. B. Vegetative characters. Loadings for the first axis (only absolute values>0.50 are given): CLL = -0.58. Loadings for the second axis: CW = -0.72, IL = -0.78.
FIGURE. Results of discriminant function analysis (DFA) for C. arenaria (ar), C. colchica (co) and C. praecox (pr). Characters abbreviated as in Table 2. A. Reproductive characters. Loadings for the first axis (only absolute values>0.50 are given): LW = -0.53, LN = -1.53, WN = 2.40, LN/WN = 2.13. Loadings for the second axis: LN = -0.56. B. Vegetative characters. Loadings for the first axis (only absolute values>0.50 are given): IL = 0.62. Loadings for the second axis: CW = 0.86, CLL = 0.78, CLW = -0.65. in Carex section Ammoglochin (Cyperaceae) in Poland
FIGURE. Results of discriminant function analysis (DFA) for C. arenaria (ar), C. colchica (co) and C. praecox (pr). Characters abbreviated as in Table 2. A. Reproductive characters. Loadings for the first axis (only absolute values>0.50 are given): LW = -0.53, LN = -1.53, WN = 2.40, LN/WN = 2.13. Loadings for the second axis: LN = -0.56. B. Vegetative characters. Loadings for the first axis (only absolute values>0.50 are given): IL = 0.62. Loadings for the second axis: CW = 0.86, CLL = 0.78, CLW = -0.65.
FIGURE. Results of discriminant function analysis (DFA) for the vegetative characters of the Ammoglochin taxa. A—along axes DF1 and DF2; B—along axes DF1 and DF3. Characters abbreviated as in Table 2. Loadings for the first axis (only absolute values>0.50 are given): SN = 0.57. Loadings for the second axis: CL = -0.91, IL = 0.54. Loadings for the third axis: CW = 0.62, CLL = -0.52, CLW = -0.89, IL = 0.51. ar—C. arenaria, br—C. brizoides, co—C. colchica, cu—C. curvata, pr—C. praecox, ps—C. pseudobrizoides, re—C. repens. in Carex section Ammoglochin (Cyperaceae) in Poland
FIGURE. Results of discriminant function analysis (DFA) for the vegetative characters of the Ammoglochin taxa. A—along axes DF1 and DF2; B—along axes DF1 and DF3. Characters abbreviated as in Table 2. Loadings for the first axis (only absolute values>0.50 are given): SN = 0.57. Loadings for the second axis: CL = -0.91, IL = 0.54. Loadings for the third axis: CW = 0.62, CLL = -0.52, CLW = -0.89, IL = 0.51. ar—C. arenaria, br—C. brizoides, co—C. colchica, cu—C. curvata, pr—C. praecox, ps—C. pseudobrizoides, re—C. repens.
FIGURE. Results of discriminant function analysis (DFA) for C. arenaria (ar), C. brizoides (br) and C. praecox (pr). Characters abbreviated as in Table 2): A. Reproductive characters. Loadings for the first axis (only absolute values>0.50 are given): UL = 0.53, UL/UW = -0.56, LN = 1.37, WN = -2.23, LN/WN = -2,03, FGL = 0.56. Loadings for the second axis: UL/UW = 0.79, LW = 0.61, LN = -0.87, WN = 0.90, LN/WN = 0.87. B. Vegetative characters. Loadings for the first axis (only absolute values>0.50 are given): CL = -0.54, IL = 0.72. Loadings for the second axis: CLL = -0.73. in Carex section Ammoglochin (Cyperaceae) in Poland
FIGURE. Results of discriminant function analysis (DFA) for C. arenaria (ar), C. brizoides (br) and C. praecox (pr). Characters abbreviated as in Table 2): A. Reproductive characters. Loadings for the first axis (only absolute values>0.50 are given): UL = 0.53, UL/UW = -0.56, LN = 1.37, WN = -2.23, LN/WN = -2,03, FGL = 0.56. Loadings for the second axis: UL/UW = 0.79, LW = 0.61, LN = -0.87, WN = 0.90, LN/WN = 0.87. B. Vegetative characters. Loadings for the first axis (only absolute values>0.50 are given): CL = -0.54, IL = 0.72. Loadings for the second axis: CLL = -0.73.
Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT00810680. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America
ClinicalTrials.gov study NCT02559583. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Trans
ClinicalTrials.gov study NCT00309881. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT01419691. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
ClinicalTrials.gov study NCT01455051. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
ClinicalTrials.gov study NCT00330252. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and
ClinicalTrials.gov study NCT01117142. IPD Sharing: Not stated. Countries: 1. Publications: 3.
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
ClinicalTrials.gov study NCT02802943. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov study NCT00868478. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
ClinicalTrials.gov study NCT03980002. IPD Sharing: NO. Countries: 1. Publications: 1.
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
ClinicalTrials.gov study NCT05183854. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.